European regulators recommend expanding once-weekly growth hormone therapy to include children born small for gestational age ...

Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate ...

For patients, this means many may be spared the physical and emotional burden of chemotherapy and its potential long-term side effects. For health systems, it represents a more efficient and ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

As many as 5,000 women a year with hormone-sensitive breast cancer could benefit ...

Millions of breast cancer patients could be spared chemotherapy with a revolutionary new genomic test, a clinical trial has shown. The most common type of cancer in women in the UK, breast cancer is ...

A new DNA test could help screen whether patients require the treatment or not, according to a new international trial.

Scientists developed a DNA or gene test that can differentiate between patients who are likely to benefit from the treatment and those who are not, a clinical trial has shown.

A study of 4,400 breast cancer patients found that more than two-thirds with low Prosigna gene-test scores could be safely treated with hormone therapy alone. | ITV National News ...

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without ...

Internet personality Clavicular shares the physical and emotional impact of stopping testosterone for four weeks, sparking ...